Total Payments
$4,812
2024 Payments
$144.50
Companies
11
Transactions
19
Medicare Patients
9,110
Medicare Billing
$224,615
Payment Breakdown by Category
Research$4,250 (88.3%)
Food & Beverage$561.90 (11.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4,250 | 1 | 88.3% |
| Food and Beverage | $561.90 | 18 | 11.7% |
Payments by Type
Research
$4,250
1 transactions
General
$561.90
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca AB | $4,250 | 1 | $0 (2018) |
| Boston Scientific Corporation | $184.38 | 4 | $0 (2023) |
| Corindus Inc. | $98.35 | 1 | $0 (2017) |
| Novo Nordisk Inc | $78.00 | 4 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $56.83 | 2 | $0 (2024) |
| Dynavax Technologies Corporation | $31.47 | 2 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $29.26 | 1 | $0 (2024) |
| Abbott Laboratories | $24.13 | 1 | $0 (2018) |
| Gilead Sciences, Inc. | $23.84 | 1 | $0 (2021) |
| Philips North America LLC | $20.63 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $144.50 | 6 | Neurocrine Biosciences, Inc. ($56.83) |
| 2023 | $187.85 | 4 | Boston Scientific Corporation ($132.62) |
| 2022 | $16.43 | 1 | Dynavax Technologies Corporation ($16.43) |
| 2021 | $38.88 | 2 | Gilead Sciences, Inc. ($23.84) |
| 2019 | $14.23 | 1 | Boston Scientific Corporation ($14.23) |
| 2018 | $4,290 | 3 | AstraZeneca AB ($4,250) |
| 2017 | $119.63 | 2 | Corindus Inc. ($98.35) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $29.61 | General |
| Category: Neuropsychiatry | ||||||
| 08/08/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $27.22 | General |
| Category: Neuropsychiatry | ||||||
| 06/27/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $29.26 | General |
| Category: Respiratory | ||||||
| 04/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Obesity | ||||||
| 02/20/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: Diabetes | ||||||
| 02/16/2024 | Philips North America LLC | (CM9) Amb Mon & Diag Und (Device) | Food and Beverage | Cash or cash equivalent | $20.63 | General |
| Category: Medical Device | ||||||
| 12/14/2023 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: Diabetes | ||||||
| 10/19/2023 | Boston Scientific Corporation | BodyGuardian (Device) | Food and Beverage | In-kind items and services | $132.62 | General |
| Category: CDS - BG Mini_RM | ||||||
| 10/19/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Diabetes | ||||||
| 05/18/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/10/2022 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: Hepatitis B Vaccine | ||||||
| 11/11/2021 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: Hepatitis B Vaccine | ||||||
| 07/26/2021 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: HCV | ||||||
| 08/23/2019 | Boston Scientific Corporation | LATITUDE (Device) | Food and Beverage | In-kind items and services | $14.23 | General |
| Category: DIAGNOSTIC | ||||||
| 11/29/2018 | AstraZeneca AB | — | — | Cash or cash equivalent | $4,250.00 | Research |
| Study: A Phase I, Open-label, Single-center Relative Bioavailability and Food Effect Randomized Crossover Study of New Granule and Capsule Formulations of Selumetinib (AZD6244) in Healthy Male Subjects | ||||||
| 05/04/2018 | Abbott Laboratories | Assurity Pacemaker (Device) | Food and Beverage | In-kind items and services | $24.13 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 02/22/2018 | BOSTON SCIENTIFIC CORPORATION | EMBLEM (Device) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: TACHY | ||||||
| 11/08/2017 | Corindus Inc. | — | Food and Beverage | In-kind items and services | $98.35 | General |
| 06/09/2017 | BOSTON SCIENTIFIC CORPORATION | EMBLEM S-ICD (Device) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: TACHY SYSTEM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase I, Open-label, Single-center Relative Bioavailability and Food Effect Randomized Crossover Study of New Granule and Capsule Formulations of Selumetinib (AZD6244) in Healthy Male Subjects | AstraZeneca AB | $4,250 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 1,545 | 2,110 | $117,455 | $39,508 |
| 2022 | 6 | 2,105 | 2,692 | $154,072 | $53,575 |
| 2021 | 5 | 2,310 | 3,117 | $166,112 | $58,705 |
| 2020 | 6 | 3,150 | 4,515 | $206,036 | $72,827 |
Total Patients
9,110
Total Services
12,434
Medicare Billing
$224,615
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 51 | 173 | $26,994 | $16,145 | 59.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 1,249 | 1,687 | $57,358 | $11,350 | 19.8% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 95 | 99 | $9,572 | $6,525 | 68.2% |
| 93307 | Ultrasound of heart | Facility | 2023 | 138 | 138 | $22,493 | $4,677 | 20.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 13 | $1,039 | $810.55 | 78.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 55 | 207 | $30,911 | $20,410 | 66.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 1,727 | 2,145 | $72,930 | $14,857 | 20.4% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 100 | 108 | $12,676 | $8,630 | 68.1% |
| 93307 | Ultrasound of heart | Facility | 2022 | 191 | 193 | $32,849 | $6,815 | 20.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 17 | 19 | $3,269 | $1,728 | 52.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 20 | $1,437 | $1,134 | 78.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 54 | 200 | $29,524 | $19,065 | 64.6% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 2,080 | 2,672 | $88,584 | $18,188 | 20.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 53 | 119 | $19,261 | $14,133 | 73.4% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 57 | 60 | $7,067 | $4,919 | 69.6% |
| 93307 | Chest ultrasound examination of heart | Facility | 2021 | 66 | 66 | $21,676 | $2,400 | 11.1% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 2,820 | 3,911 | $121,443 | $27,300 | 22.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 75 | 329 | $45,524 | $27,035 | 59.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 47 | 62 | $9,419 | $6,786 | 72.0% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 75 | 77 | $8,927 | $6,375 | 71.4% |
| 93307 | Chest ultrasound examination of heart | Facility | 2020 | 119 | 119 | $19,278 | $4,334 | 22.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 14 | 17 | $1,446 | $997.29 | 69.0% |
About Warren Smith
Warren Smith is a Specialist healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1831165000.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Warren Smith has received a total of $4,812 in payments from pharmaceutical and medical device companies, with $144.50 received in 2024. These payments were reported across 19 transactions from 11 companies. The most common payment nature is "" ($4,250).
As a Medicare-enrolled provider, Smith has provided services to 9,110 Medicare beneficiaries, totaling 12,434 services with total Medicare billing of $224,615. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Cardiovascular Disease
- Location Baltimore, MD
- Active Since 02/27/2006
- Last Updated 06/30/2022
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1831165000
Products in Payments
- BodyGuardian (Device) $132.62
- Ozempic (Drug) $60.00
- INGREZZA (Drug) $56.83
- Heplisav-B (Drug) $31.47
- AIRSUPRA (Drug) $29.26
- Assurity Pacemaker (Device) $24.13
- Epclusa (Drug) $23.84
- EMBLEM S-ICD (Device) $21.28
- (CM9) Amb Mon & Diag Und (Device) $20.63
- Wegovy (Drug) $18.00
- EMBLEM (Device) $16.25
- VERQUVO (Drug) $15.01
- LATITUDE (Device) $14.23
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Baltimore
Mr. James Gammie, M.d, M.D
Specialist — Payments: $29.8M
Specialist $29.8M
Dr. Richard Adler, M.d, M.D
Specialist — Payments: $3.1M
Specialist $3.1M
Dr. Philip Levin, M.d, M.D
Specialist — Payments: $921,481
Specialist $921,481
Dr. Agha Khan, Md, MD
Specialist — Payments: $170,581
Specialist $170,581
W. Eglseder, M.d, M.D
Specialist — Payments: $57,679
Specialist $57,679
Bartley Griffith, M.d, M.D
Specialist — Payments: $49,695
Specialist $49,695